08:23 AM EDT, 06/05/2025 (MT Newswires) -- Immunic ( IMUX ) said Thursday it has completed enrollment of participants in two phase 3 studies of lead asset vidofludimus calcium in patients with relapsing multiple sclerosis.

The company said it enrolled more than 2,200 patients at over 100 sites in 15 countries for the two studies and expects the top-line data by the end of 2026.

Immunic ( IMUX ) also said additional data from a phase 2 trial in progressive multiple sclerosis showed vidofludimus calcium's neuroprotective potential and ability to slow disease progression in multiple sclerosis patients with or without focal inflammation.

Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases.

Immunic's ( IMUX ) stock was up more than 2% in recent premarket activity Thursday.